ELRIG Drug Discovery 2026 has ended. This guide stays up as the record of who was there. Next: ELRIG DD 2027, Oct 19–20, 2027 in Liverpool
CRISPR and gene editing at ELRIG Drug Discovery 2026
Oct 14–15, 2026 London, UK ~3k attendees Website
18 organizations at ELRIG Drug Discovery 2026 present work in CRISPR and gene editing: 12 technology and service providers, 5 academic, government and non-profit bodies and 1 drug developer. Between them they bring 27 presentations to the program. Most represented: AstraZeneca, University College London and The Francis Crick Institute. As of Oct 8, 2026.
Format
Top represented
Showing 1–13 of 18 organizations
| Organization | ELRIG Drug Discovery 2026 Attendance |
|---|---|
AstraZeneca Cambridge, UK | ◆Partner |
Global biopharmaceutical company discovering and developing medicines in oncology, rare disease, and cardiovascular, renal, metabolic and respiratory disease. | Booth Exhibiting at Booth CZ01 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Chair Wed Oct 14 11:15am–11:20am Track Chair - CRISPR/Cas technologies from discovery to therapeutic application How CRISPR gene editing is used from finding drug targets to engineering cell and gene therapies, and where it may go next. Chair Wed Oct 14 11:15am–11:20am Track Chair - Next-gen biophysics How biophysics has shaped drug discovery from checking targets to refining lead compounds, and how newer methods can speed programmes up. Talk Wed Oct 14 11:20am–11:50am Talk Wed Oct 14 11:50am–12:20pm Automating In Vivo Antibody Discovery How a manual B-cell processing workflow was automated to reduce operator variability and raise throughput while preserving cell quality. Talk Wed Oct 14 12:20pm–12:50pm Talk Wed Oct 14 2:40pm–3:10pm Talk Wed Oct 14 3:10pm–3:45pm To PhD or not to PhD? Navigating Life Sciences careers as an ECP Whether early career scientists gain more from a doctorate or from hands-on experience, and how people actually build life science careers. Panel Wed Oct 14 4:30pm–5:00pm Talk Wed Oct 14 4:30pm–5:00pm Talk Thu Oct 15 12:40pm–1:10pm Talk Thu Oct 15 3:30pm–4:00pm |
University College London London, UK | |
Public research university in London. | Talk Wed Oct 14 3:45pm–4:15pm Talk Thu Oct 15 12:40pm–1:10pm |
The Francis Crick Institute London, UK | |
Biomedical research institute in London. | Chair Wed Oct 14 11:15am–11:20am Track Chair - CRISPR/Cas technologies from discovery to therapeutic application How CRISPR gene editing is used from finding drug targets to engineering cell and gene therapies, and where it may go next. |
Wellcome Sanger Institute Hinxton, UK | |
Genomics research institute near Cambridge, UK. | Talk Wed Oct 14 2:00pm–2:30pm |
FG Functional Genomics Centre Cambridge, UK | |
AstraZeneca and Cancer Research Horizons collaboration running CRISPR screens to find and validate cancer drug targets. | Talk Wed Oct 14 12:20pm–12:50pm |
IFLScience London, UK | |
Popular science news website and publisher. | Talk Wed Oct 14 10:30am–11:15am |
Milner Therapeutics Institute Cambridge, UK | |
University of Cambridge institute linking academic research with industry to find new therapeutic targets. | |
bit.bio Cambridge, UK | |
Programmes iPSCs into specific human cell types with its opti-ox technology, selling ioCells including disease-model, CRISPR-ready and reporter lines. | Booth Exhibiting at Booth K04 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 2:35pm–2:40pm |
Genome engineering partner making knockout, knock-in and tagged cell lines and selling CRISPR knockout kits and arrayed libraries. | Booth Exhibiting at Booth H02 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 12:50pm–12:55pm |
MaxCyte Rockville, MD | |
ExPERT electroporation systems for cell engineering from discovery to manufacturing, plus SeQure genotoxicity services for cell and gene therapies. | Booth Exhibiting at Booth K33 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 12:50pm–12:55pm |
Myllia Vienna, Austria | |
Runs CRISPR screens in primary human cells with single-cell RNA readouts, generating perturbation data for target discovery and AI models. | Booth Exhibiting at Booth F06 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 2:30pm–2:35pm |
PartitionBio Cambridge, UK | |
Makes BubbleFect, a non-viral, lipid-free delivery reagent based on phase-separated condensates for getting mRNA, CRISPR cargo and proteins into hard-to-transfect cells. | Booth Exhibiting at Booth S19 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 12:50pm–12:55pm |
Trince Ghent, Belgium | |
Ghent University spin-off making LumiPore, a laser photoporation platform that delivers molecules into hard-to-transfect adherent and suspension cells. | Booth Exhibiting at Booth J20 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 4:15pm–4:30pm Photoporation Enables Plate-Based and Spatially Controlled CRISPR-Cas9 Gene Editing in Adherent Cell Models Using laser-activated nanoparticles to open cell membranes briefly so CRISPR editing tools enter cells growing in ordinary assay plates, even in chosen areas. |
Instantly find 20 buyers in CRISPR and gene editing
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ELRIG Drug Discovery 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by ELRIG. Submit a correction